Hsi Andy C, Hurley M Yadira, Lee Sena J, Rosman Ilana S, Pang Xiaofan, Gru Alejandro, Schaffer András
Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, USA.
Department of Dermatology, Saint Louis University School of Medicine, Saint Louis, MO, USA.
J Cutan Pathol. 2016 Apr;43(4):354-61. doi: 10.1111/cup.12668. Epub 2016 Feb 10.
Mantle cell lymphoma (MCL) is associated with the worst prognosis among low-grade B-cell lymphomas. While cutaneous involvement by nodal or systemic MCL is uncommon, its differentiation from primary cutaneous B-cell lymphoma (CBCL) or cutaneous involvement by other extra-cutaneous BCL is challenging as neither histomorphology nor immunophenotype can be absolutely specific. We analyzed the diagnostic utility of SOX11 immunohistochemistry in differentiating secondary cutaneous MCL from other low-grade CBCL.
Immunohistochemical staining with anti-SOX11 antibody was performed on 8 cases of secondary cutaneous MCL, 16 secondary cutaneous CLL, 20 primary cutaneous MZL, 12 cutaneous FCL (6 primary, 6 secondary), 7 primary cutaneous DLBCL, leg type, 5 systemic DLBCL and 3 B-ALL. SOX11 and cyclin D1 staining were compared in secondary cutaneous MCL.
Nuclear SOX11 staining was seen in seven of eight cases (88%) of secondary cutaneous MCL, including a case with minimal cyclin D1 expression. All other CBCL lacked detectable nuclear SOX11 expression. The sensitivity and specificity for SOX11 in MCL were 87.5 and 100%, respectively. Both the sensitivity and specificity for combined SOX11 and cyclin D1 immunohistochemistry were 100%.
SOX11 immunohistochemistry could be a useful adjunct in distinguishing secondary cutaneous MCL from other CBCL.
套细胞淋巴瘤(MCL)在低度B细胞淋巴瘤中预后最差。虽然淋巴结或全身性MCL累及皮肤并不常见,但将其与原发性皮肤B细胞淋巴瘤(CBCL)或其他皮肤外B细胞淋巴瘤累及皮肤相鉴别具有挑战性,因为组织形态学和免疫表型都不是绝对特异的。我们分析了SOX11免疫组化在鉴别继发性皮肤MCL与其他低度CBCL中的诊断效用。
用抗SOX11抗体进行免疫组化染色,检测8例继发性皮肤MCL、16例继发性皮肤慢性淋巴细胞白血病(CLL)、20例原发性皮肤黏膜相关淋巴组织淋巴瘤(MZL)、12例皮肤滤泡性淋巴瘤(FCL,6例原发性,6例继发性)、7例原发性皮肤弥漫大B细胞淋巴瘤(腿型)、5例全身性弥漫大B细胞淋巴瘤和3例B淋巴细胞白血病(B-ALL)。比较继发性皮肤MCL中SOX11和细胞周期蛋白D1的染色情况。
8例继发性皮肤MCL中有7例(88%)可见细胞核SOX11染色,包括1例细胞周期蛋白D1表达极少的病例。所有其他CBCL均未检测到细胞核SOX11表达。SOX11在MCL中的敏感性和特异性分别为87.5%和100%。SOX11和细胞周期蛋白D1联合免疫组化的敏感性和特异性均为100%。
SOX11免疫组化在鉴别继发性皮肤MCL与其他CBCL中可能是一种有用的辅助手段。